The FDA approves mass-manufactured, standardized drug products rather than custom-mixed medications prepared for individual patients in pharmacies
Markey KA, Ottridge R, Mitchell JL et al (2017) Assessing the Efficacy and Safety of an 11beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitor (AZD4017) in the Idiopathic Intracranial Hypertension Drug Trial, IIH:DT: Clinical Methods and Design for a Phase II Randomized Controlled Trial
Z., Nilsson, M
Additionally, significant improvements in NYHA class and NT-proBNP levels were observed at one year
According to Celltrion, Steqeyma was approved based in part on the findings of a Phase III study in plaque psoriasis, which demonstrated that the biosimilar had no clinically meaningful differences versus Stelara in terms of efficacy or safety
Studies have confirmed that TMAO plays an important role in inducing foam cell formation and vascular inflammation by up-regulating the MAPK/JNK pathway and MAPK/ERK pathway (Wu et al., 2019)